C4 Therapeutics is discontinuing one of its cancer assets after a phase 1/2 trial proved the drug ineffective. The small molecule medicines biotech has ended development of CFT8634, an oral BRD9 ...
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results